Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Naxitamab, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Combination With Induction Chemotherapy for Patients With Newly-Diagnosed High-Risk Neuroblastoma

NCT07537400 is registered in ClinicalTrials.gov with Shaare Zedek Medical Center as lead sponsor.

NCT NCT07537400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07537400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Naxitamab, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Combination With Induction Chemotherapy for Patients With Newly-Diagnosed High-Risk Neuroblastoma
Lead sponsor
Shaare Zedek Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
June 23, 2026
Completion date
April 30, 2032
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk neuroblastoma